Article Abstract

A new paradox for pCR in BRCA mutation carriers

Authors: Konstantinos Rounis, Dimitrios Mavroudis

Abstract

Pathologic complete response (pCR) in neoadjuvant chemotherapy (NACT) in breast cancer and especially in the triple negative subtype (TNBC) is considered an important surrogate end point for disease free survival (DFS), event free survival (EFS) and overall survival (OS) (1). Breast tumors of patients carrying a germline BRCA1/2 mutation represent a subgroup with unique biological characteristics (2).

Article Options

Download Citation